Desmopressin Acetate
Alias : Sodium deoxyribose cytidylic acid,DDAVP
Cas No. : 16789-98-3
Formule moléculaire : C46H64N14O12S2
Masse moléculaire :1189.32
Pureté (CLHP) : 98.0%min.
Apparence : poudre blanche
Single Impurity (CLHP) : 0.5%max
Composition en acides aminés : ±10% de la théorie
Teneur en peptides (N %) : ≥80,0 %
Teneur en eau (Karl Fischer) : ≤8.0%
Teneur en acétate (HPIC) : ≤12.0%
Équilibre de la masse : 95.0~105,0 %
Stockage: Closed, below 2 ~ 8°C preservation
Usage : Desmopressin Acetate is used for nocturnal enuresis, coagulation disorders and diabetes insipidus.
La description:
Desmopressin (trade names: DDAVP, DesmoMelt, Minirin, Minirin Melt, Octim, Stimate) is a synthetic replacement for vasopressin, the hormone that reduces urine production. It may be taken nasally, intravenously, or as an oral or sublingual tablet. Physicians prescribe desmopressin most frequently for treatment of diabetes insipidus, bedwetting, or nocturia.
Application :
Doctors prescribe desmopressin frequently for treatment of nocturnal enuresis (bedwetting). It is usually prescribed in the form of oral desmopressin acetate, DDAVP. Patients taking DDAVP are 4.5 times more likely to sleep without disruption compared with placebo.
Desmopressin can be used to promote the release of von Willebrand factor (with subsequent increase in factor VIII survival secondary to vWF complexing) in patients with coagulation disorders such as von Willebrand disease, mild hemophilia A (factor VIII deficiency), and thrombocytopenia. It can be used with uremic induced platelet dysfunction. It is not effective in the treatment of hemophilia B (factor IX deficiency), severe hemophilia A, or von Willebrand.
Desmopressin is used in the treatment of central diabetes insipidus (DI), to replace endogenous ADH that is missing in the central nervous system type of this disorder (decreased production of ADH from the posterior pituitary). It is also used in the diagnostic workup for diabetes insipidus, in order to distinguish central from nephrogenic DI.
